PTC Therapeutics (NASDAQ:PTCT) Trading Up 4.8% Following Analyst Upgrade
PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s share price rose 4.8% on Tuesday after Robert W. Baird raised their price target on the stock from $48.00 to $52.00. Robert W. Baird currently ...
PTC Therapeutics (NASDAQ:PTCT) Reaches New 12-Month High After Analyst Upgrade
PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) reached a new 52-week high during mid-day trading on Wednesday after Robert W. Baird raised their price target on the stock from $48.00 to $52.00 ...
PTC Inc. (NASDAQ:PTC) Receives $204.83 Average Target Price from Brokerages
Shares of PTC Inc. (NASDAQ:PTC – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are presently covering the firm, MarketBeat.com reports. Four ...
PTC Therapeutics (NASDAQ:PTCT) Rating Lowered to Hold at StockNews.com
StockNews.com downgraded shares of PTC Therapeutics (NASDAQ:PTCT – Free Report) from a buy rating to a hold rating in a ...
The Pharma Letter14h
PTC picks up $150 million via voucher sale
PTC Therapeutics has sold its rare pediatric disease priority review voucher (PRV) for $150 million, following FDA approval ...
Vertex leads J.P. Morgan's top biotech picks list for 2025
J.P. Morgan said its top biotech picks for 2025 were Vertex, Travere, SpringWorks, PTC Therapeutics, Wave Life Sciences, ...
PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the global Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of slowing disease progression on the composite ...
The Pharma Letter1d
PTC halts development of ALS drug after trial miss
PTC Therapeutics' Phase II trial for utreloxastat in ALS failed to meet its primary endpoint, showing no significant ...
Nasdaq6d
What to Expect from Zoom Video Comms's Earnings
Zoom Video Comms (NASDAQ:ZM) is set to give its latest quarterly ... and average 1-year price targets of Tyler Technologies, PTC and Ansys, three significant industry players, providing valuable ...
ETF Daily News3d
Advisors Asset Management Inc. Boosts Stock Position in PTC Inc. (NASDAQ:PTC)
PTC Price Performance Shares of NASDAQ:PTC opened at $200.59 on Tuesday. PTC Inc. has a 12 month low of $153.44 and a 12 month high of $201.66. The firm has a market capitalization of $24.10 ...
Yahoo Finance3d
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., Nov. 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 20, 2024, the company approved non-statutory stock options to purchase an aggregate ...
PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the ...